BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer
Dr Gil Morgan from OncoAlert gives his oncology highlights from social media from day 3 of ASCO 2021.
Alerts cover trials such as KEYNOTE-564, OlympiA, VISION, RELATIVITY-047, JUPITER-02, and CheckMate648.
Dr Morgan ends on a question from a colleague in Brazil asking, why is there a difference in translating clinical trials results to clinical practice depending on subspecialties? Comparing the results of OlympiA to those of Adaura.
You can watch Dr Morgan's previous roundup here
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer
BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer
Burden and trends of breast cancer worldwide: Opportunities for prevention?
The added value of integrative medicine
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
GIST tumours and soft tissue sarcomas
Best practice in HRRm testing in patients with metastatic prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
OncoAlert Round Up for August 25th - 31st, 2023